Nurix Therapeutics officer proposes $104K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Gwenn M. Hansen reported a proposed sale of 5,394 common shares, with an aggregate market value of $104,104.20. The approximate sale date is June 25, 2026, through Morgan Stanley Smith Barney LLC. Hansen acquired 5,394 shares from the issuer as restricted stock units on April 30, 2026; the notice lists a Rule 10b5-1 plan adoption or instruction date of February 26, 2026. It also lists Hansen’s sale of 3,214 common shares on April 30, 2026, for gross proceeds of $53,497.99.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Units financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.